Meeting
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
Authors
Akito Hata
Department of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan
Akito Hata , Nobuyuki Katakami , Naoto Takase , Kayoko Kibata , Yuta Yamanaka , Motohiro Tamiya , Masahide Mori , Takashi Kijima , Satoshi Morita , Kazuko Sakai , Kazuto Nishio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000030545
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9117)
DOI
10.1200/JCO.2022.40.16_suppl.9117
Abstract #
9117
Poster Bd #
103
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).
First Author: Pasi A. Janne
Poster
2013 ASCO Annual Meeting
Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations.
First Author: Leena Gandhi
Poster
2018 ASCO Annual Meeting
Upfront next generation sequencing in NSCLC: A publicly funded perspective.
First Author: Kirstin Perdrizet
Poster
2017 ASCO Annual Meeting
Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.
First Author: Qiuxiang Ou